Bristol-Myers, Novartis deal

Bristol-Myers and Novartis partnered to run two Phase I/II trials to evaluate combinations of BMS's Opdivo nivolumab with three Novartis compounds to treat non-small cell lung cancer (NSCLC). The Nova...